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Abstract: This review focuses on the use of oxadiazoles as translational readthrough-inducing drugs
(TRIDs) to rescue the functional full-length protein expression in mendelian genetic diseases caused
by nonsense mutations. These mutations in specific genes generate premature termination codons
(PTCs) responsible for the translation of truncated proteins. After a brief introduction on nonsense
mutations and their pathological e↵ects, the features of various classes of TRIDs will be described
discussing di↵erences or similarities in their mechanisms of action. Strategies to correct the PTCs
will be presented, particularly focusing on a new class of Ataluren-like oxadiazole derivatives in
comparison to aminoglycosides. Additionally, recent results on the e ciency of new candidate TRIDs
in restoring the production of the cystic fibrosis transmembrane regulator (CFTR) protein will be
presented. Finally, a prospectus on complementary strategies to enhance the e↵ect of TRIDs will be
illustrated together with a conclusive paragraph about perspectives, opportunities, and caveats in
developing small molecules as TRIDs.
Keywords: premature termination codon; nonsense mutation; translational readthrough inducing
drugs; ataluren; oxadiazoles; cystic fibrosis
1. Introduction
Protein synthesis is a crucial phase for any living organism; therefore, any phenomenon a↵ecting
any of the steps involved in such a crucial process could jeopardize life itself or cause severe disorders.
Protein synthesis, in the classical vision of the central dogma, consists of two steps: transcription
and translation (Figure 1) [1–3]. Therefore, any strategy aiming at correcting miscarried protein
syntheses should intervene before the synthetic process is completed. In eukaryotic cells, as opposed
to prokaryotic cells (Figure 1, left), transcription and translation are spatially and temporally separated,
since transcription, which is followed by pre-mRNA processing, takes place in the nucleus, while
translation occurs in the cytoplasm (Figure 1, right). The mature mRNA exits the nucleus, reaches
the cytoplasm, where the ribosome ties itself to the mRNA’s start codon, and begins the translation
process to produce a peptide chain. Protein synthesis goes on until the ribosome meets a stop triplet
(UGA, UAA, or UAG), thus ending translation and releasing the synthesized polypeptide [4].
Int. J. Mol. Sci. 2019, 20, 3329; doi:10.3390/ijms20133329 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2019, 20, 3329 2 of 18
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 2 of 18 
 
 
Figure 1. Steps involved in protein synthesis in prokaryotic (left) and eukaryotic cells (right). 
In this context, mutations are alterations in the DNA sequence that are reflected in the gene 
transcript and, when nonconservative, can result in the production of nonfunctional proteins or even 
hinder protein expression. Among all types of mutations, base substitutions (also known as point 
mutations) are the most common and can belong to the classes of silent, missense, or nonsense 
mutations [5]. Silent mutations are harmless since they change a codon for a different one that codes 
for the same amino acid, thus resulting in the production of a protein identical to the wild-type one. 
Missense mutations, instead, lead to a codon that would be translated into a different amino acid 
with respect to the wild type; this mutation would have deleterious effects on the functionality of the 
resulting protein only when the new amino acid has different properties with respect to the one coded 
in the wild-type gene. Finally, nonsense mutations are the most dangerous point mutations. In fact, 
when UGA, UAA, and UAG codons appear earlier in the mRNA sequence, with respect to the normal 
stop signal, nonsense mutations are interpreted as a premature termination codon (PTC). Once the 
ribosome encounters a PTC in its acceptor (A) site, translation will be terminated, producing then a 
truncated and nonfunctional protein. This could lead to severe forms of various diseases, unless the 
truncation occurs in nonfunctional terminal parts of the wild-type protein [6]. Since truncated 
polypeptides synthesized from these aberrant transcripts could be toxic to normal cellular functions, 
mammalian cells evolved a mechanism to monitor the quality of mRNAs. Thus, the transcripts 
harboring a PTC are subject to degradation by the nonsense-mediated mRNA decay (NMD) pathway 
[7]. 
Unfortunately, nonsense mutations are the cause of about 11% of all genetic disorders in humans 
[8,9]. In particular, it was observed that stop mutations are associated to disorders such as cystic 
fibrosis (CF) [6], Duchenne muscular dystrophy (DMD) [10], spinal muscular atrophy [11,12], 
neurofibromatosis [13], retinitis pigmentosa [14,15], lysosomal storage disease [16], ataxia 
telangiectasia (AT) [17], Hurler’s syndrome (HS) [6], Rett syndrome [18], Shwachman–Diamond 
syndrome [19], Usher’s syndrome (USH) [20], Hemophilia A and B [21], Tay–Sachs disease [22], and 
several forms of cancer [23]. 
Therefore, exploring novel therapeutic approaches for the treatment of such a wide range of 
diseases caused by PTCs would make a significant contribution to improve the health conditions of 
many patients [24]. While some therapies aim at diminishing the impact of symptoms of these 
diseases, recent research is facing the challenge of targeting the genetic defect itself, in the frame of a 
personalized medicine approach. On one hand, correction of the genetic defect at the DNA level has 
been attempted by genome editing strategies in order to override nonsense mutations during 
transcription [25–28]. On the other hand, drugs have been developed to target the translation phase 
and promote the bypass of the PTC, allowing the synthesis of full-length functional proteins, a 
strategy known as PTC “readthrough” [9,24,29,30]. This review illustrates the different classes of 
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resulting protein only when the new amino acid has di↵erent properties with respect to the one coded in
the wild-type gene. Finally, nonsense mutations are the most dangerous point mutations. In fact, when
UGA, UAA, and UAG codons appear earlier in the mRNA sequence, with respect to the normal stop
signal, nonsense mutations are interpreted as a premature termination codon (PTC). Once the ribosome
encounters a PTC in its acceptor (A) site, translation will be terminated, producing then a truncated
and nonfunctional protein. This could lead to severe forms of various diseases, unless the truncation
occurs in nonfunctional terminal parts of the wild-type protein [6]. Since truncated polypeptides
synthesized from these aberrant transcripts could be toxic to normal cellular functions, mammalian
cells evolved a mechanism to monitor the quality of mRNAs. Thus, the transcripts harboring a PTC
are subject to degradation by the nonsense-mediated mRNA decay (NMD) pathway [7].
Unfortunately, nonsense mutations are the cause of about 11% of all genetic disorders in
humans [8,9]. In particul r, it was observed that stop mutations are ass ciated to disorders such as
cystic fibrosis (CF) [6], Duch nne m scular dystrophy ( MD) [10], spinal m scul r atrophy [ 1,12],
neurofibromatosi [13], retinitis pigmentosa [14,15], lysosomal st rage dise s [16], ataxia telangiect sia
(AT) [17], Hurler’s syndrome (HS) [6], Rett syndrome [18], Shwachman–Diamond syndro e [19],
Usher’s syndrome (USH) [20], Hemophilia A and B [21], Tay–Sachs disease [22], and sev ral forms of
cancer [23].
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Therefore, exploring novel therapeutic approaches for the treatment of such a wide range of
diseases caused by PTCs would make a significant contribution to improve the health conditions
of many patients [24]. While some therapies aim at diminishing the impact of symptoms of these
diseases, recent research is facing the challenge of targeting the genetic defect itself, in the frame of
a personalized medicine approach. On one hand, correction of the genetic defect at the DNA level
has been attempted by genome editing strategies in order to override nonsense mutations during
transcription [25–28]. On the other hand, drugs have been developed to target the translation phase
and promote the bypass of the PTC, allowing the synthesis of full-length functional proteins, a strategy
known as PTC “readthrough” [9,24,29,30]. This review illustrates the di↵erent classes of drugs that
have been developed so far, in order to promote the readthrough of premature stop codons, focusing
particularly on oxadiazole derivatives, their proposed mechanism of action, and recent results in
restoring the production of the full-length cystic fibrosis transmembrane regulator (CFTR) protein.
2. Concepts behind Readthrough Approaches
Since nonsense mutations alter polypeptide synthesis, eventually leading to truncated proteins
(Figure 2A), the main goal of readthrough approaches is to restore the production of a functional
protein that, even in small amounts, can diminish the symptoms of nonsense disorders. Considering
that protein synthesis is carried out on ribosomes, the latter is the logical place where the desired
correction should occur. In this context, di↵erent small molecules have been developed as nonsense
suppressors (NonSups), or translational readthrough-inducing drugs (TRIDs) [31], to fool the ribosomal
machinery during recognition of the PTC as a stop signal, thus avoiding the premature ending of
protein synthesis [9]. However, because there are a number of actors (mRNA, tRNA, release factors,
ribosomal subunits, etc.) involved in peptide synthesis, TRIDs can a↵ect various biomolecular targets,
leading to di↵erent types of readthrough (Figure 2B–D). The ideal readthrough process (Figure 2B)
should be highly specific and rely on: (i) a su cient level of mRNA that survived NMD degradation
to restore enough functional full-length protein; (ii) insertion of the correct amino acid (the same as
that coded by the wild-type gene) at the point of the sequence that would have been interrupted by the
premature stop; and (iii) recognition of the normal termination codon (NTC in Figure 2) that leads
to the correct termination of protein synthesis. Therefore, ideal TRIDs should be able to distinguish
between normal and premature termination codons to achieve the synthesis of a functional full-length
protein. However, if TRIDs induce the insertion of a di↵erent amino acid (with respect to the wild type)
(Figure 2C) or just skip the PTC, continuing peptide synthesis without inserting any amino acid in the
place of the PTC (Figure 2D), this could cause a misfunction of the resulting protein [22]. This could
lead, for instance, to uncorrected folding, hindering the subcellular localization of the protein in its
normal site of action or, in case of a channel protein, to narrower channels that inhibit the normal flow
of ions. Moreover, if TRIDs act also as (or are used in conjunction with) NMD inhibitors to implement
the RNA levels to readthrough, it must be considered that interaction with the NMDmechanism could
be a problem for the cells, leading to the survival of other mutant mRNAs that should be degraded.
In this context, the first class of small molecules that showed activity as TRIDs was that of
aminoglycoside antibiotics [32], later followed by the discovery of Ataluren [33] and its oxadiazole
analogues [29,34,35]. These have been tested both in vitro and in vivo, observing their interaction
with biomolecules involved in protein synthesis or their interference with the mechanism of NMD [9].
However, the detailed mechanism of action of these new readthrough inducers is still uncertain, and
this is the main reason for current limited use of TRIDs for human therapy. The following paragraphs
describe the activity of various classes of TRIDs, comparing hypotheses and data on their mechanism
of action.
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Figure 2. (A) Translation of premature termination codon (PTC)-containing mRNA in the absence of
translational readthrough-inducing drugs (TRIDs); (B) ideal readthrough of PTC; (C) readthrough
inserting a cognate amino acid; and (D) readthrough skipping amino acid insertion. Figure legend:
mRNA, RNA messenger; tRNA, RNA transfer; 40S and 60S, small and large ribosome subunit,
respectively; eEF1A, eukaryotic translation elongation factor 1A; eRF1 and eRF3, eukaryotic translation
termination factor 1 and 3, respectively; and GTP, guanosine-5’-triphosphate.
3. Classes of Translational Readthrough-Inducing Drugs (TRIDs)
3.1. Aminoglycosides
Aminoglycosides are derivatives of polyamino oligosaccharides commonly used as antibiotics to
treat Gram-negative antibacterial infections [36]. In fact, they are capable of binding to the site of the
bacterial small ribosome unit that generally controls codon–anticodon interactions between mRNA
and tRNA [37]. Considering their ribosomal activity, compounds such as gentamicin, tobramycin,
paromomycin, and geneticin (Figure 3) were also studied for their readthrough-inducing features.
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Most studies have demonstrated that tobramycin has low e ciency as a PTC suppressor, while
gentamicin is very e cient as a TRID although it presents an undesirable toxic profile because of its
ototoxicity and nephrotoxicity [38]. Some studies have demonstrated that the activity of aminoglycoside
TRIDs varies depending on the stop codon sequence (UGA, UAA, or UAG) [32,39,40]. Moreover,
the negative side e↵ects of this class of drugs as TRIDs are also due to the readthrough of correctly
positioned stop codons, thus demonstrating a lack of selectivity towards the premature stop codon.
Additionally, aminoglycoside antibiotics cannot be used for long-term therapy (as it would be required
by their use as TRIDs) because of the risk of inducing bacterial resistance [37]. An interesting alternative
to gentamicin is represented by ELX-02 (Figure 4), a synthetic aminoglycoside that binds eukaryotic
ribosomes and has been recently claimed to induce the readthrough of PTCs without the toxicity of
the antibiotics.
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The first study showed that ELX-02 is capable both to restore the synthesis of the CFTR protein in
the presence of nonsense mutations and to increase the levels of mRNA, which indicates that the drug
is capable to interact with the NMDmechanism and/or to stabilize the transcript [37,41].
ELX-02 exercises its readthrough activity by stabilizing the “exo” conformation of two adenosine
residues in rRNA. Because of this conformation, a near-cognate tRNA can bind the PTC, shifting aside
eRF1. In this way, protein synthesis will continue beyond the PTC in order to generate a full-length
protein. ELX-02 shows greater selectivity for cytoplasmic ribosomes than gentamicin, which results
in increased readthrough activity and lower toxicity. In fact, aminoglycoside toxicity is determined
by its a nity for mitochondrial ribosomes, and ELX-02’s a nity for this site is 100-fold lower than
other aminoglycoside antibiotics. As for clinical studies, ELX-02 underwent randomized double-blind
placebo-controlled trials. It was administered subcutaneously in doses of 0.3 to 7.5 mg/kg and
intravenously in doses of 0.3 mg/kg. These studies confirmed that ELX-02 administered subcutaneously
is widely bioavailable, well-tolerated, and does not present toxic e↵ects, such as nephrotoxicity and
ototoxicity, when administered in doses within the therapeutic range [37].
3.2. Oxadiazoles
Oxadiazoles are aromatic heterocyclic rings containing one oxygen and two nitrogen atoms
occupying di↵erent ring positions as in 1,2,3- [42], 1,2,4- [43,44], 1,2,5- [45], and 1,3,4-oxadiazoles [46,47]
(Figure 5). Depending on the relative position of nitrogen and oxygen atoms, these classes of
oxadiazoles possess di↵erent characteristics. For instance, 1,2,4-oxadiazoles have lower water
solubility than 1,3,4-oxadiazoles because of the reduced hydrogen bond acceptor character of the
nitrogen in 1,2,4-oxadiazole ring [43]. Moreover, they have been extensively studied because of their
peculiar reactivity [43,48] and possible applications in material chemistry [49–55] or as bioactive
compounds [44,56–58].
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Of all the four possible classes of oxadiazoles, 1,2,4- and 1,3,4-oxadiazoles are the most studied for
their pharmaceutical properties [59]. Their heterocyclic core is present in commercial drugs, such as
the antitussive oxolamine (Perebron®) [60] and antiviral (Raltegravir®) [61], or potential anticancer
drug candidates [62].
In 2007, a fluorinated 1,2,4-oxadiazole, specifically the 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-
3-yl]-benzoic acid also known as Ataluren or PTC124 (Figure 6), was reported to promote the
readthrough of nonsense mutations [33]. Ataluren is capable of promoting the readthrough of UGA,
UAG, and UAA codons, but it shows the highest readthrough activity for the UGA codon [6,33]. Since
Ataluren is structurally di↵erent from aminoglycosides, its discovery opened the way to a di↵erent
class of drugs able to treat genetic disorders caused by nonsense mutations. Additionally, its activity
profile within a 0.01–3 µM therapeutic range was better than that of gentamicin aminoglycoside, which
was active as a TRID at much higher concentrations [6,33]. Furthermore, Ataluren is able to distinguish
between normal and premature stop codons, thus inducing selective readthrough of PTCs without
showing the typical toxicity of aminoglycosides. Indeed, several clinical trials have emphasized the
safety and tolerability of Ataluren, even for long-term treatments [6,33,63].
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Today, Ataluren is marketed r the trade name of Translarna® and has been approved
as a therapy for ambulatory patients aged five years and older a↵e t d by Duchenne muscular
dystrophy [64]. However, its us is not generally extensibl to a wide range of cases since ot all
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patients su↵ering from pathologies caused by nonsense mutations found beneficial e↵ects, especially if
Ataluren is administered in conjunction with other drugs [65]. For instance, in an Ataluren clinical trial
performed on patients a↵ected by cystic fibrosis, and taking tobramycin by inhalation, the competitive
action between Ataluren and aminoglycoside antibiotics was highlighted [65]. This competition
could be due to the fact that Ataluren also targets the ribosomal machinery as well as tobramycin,
although the actual biomolecular target could be di↵erent for the two drugs. Indeed, Ataluren’s
readthrough activity has been questioned [66–68], and its detailed mechanism of action is still debated,
despite the fact that the functionality of rescued full-length proteins has been demonstrated [69,70]
and consensus is converging towards its interaction with mRNA [71]. Confirmation of Ataluren’s
readthrough activity by orthogonal in vitro assays [72] prompted researchers to optimize this lead
compound by designing Ataluren’s analogues that could be used for the treatment of diseases
caused by nonsense mutations. The modification of Ataluren’s sca↵old could involve either the
oxadiazole heterocyclic core or the attached lateral moieties. In this context, and in the absence of a
certain biomolecular target, computational optimization of Ataluren’s analogues could be achieved by
ligand-based virtual screening. Thus, virtually selected sets of molecules containing either the 1,2,4- or
the 1,3,4-oxadiazole core were synthesized and experimentally tested by FLuc cell-based assays to
evaluate their readthrough ability [29,34,35,72]. In particular, Hela cells were transfected with pFLuc
wild-type (pFLuc-wt) or pFLuc-opal (containing the UGA stop codon) plasmids. The expression of
FLuc gene was then evaluated bymeasuring the luminescence of the produced luciferase in cells treated
with the tested derivatives. However, Auld et al. [67] questioned the validity of FLuc cell-based assays
as a method to evaluate the readthrough activity of Ataluren and its analogues, claiming that these
compounds stabilized FLuc, protecting it from its degradation by trypsin. Therefore, an orthogonal
assay was developed to confirm the readthrough activity of the new compounds that were the most
active according to the Fluc assay (Figure 7A).
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the st active compounds compared with untreat d cells and with Fluc u ed as positive control;
(B) I nofluorescence of IB3.1 cells untreated (Untr; negative control) o treated with PTC124
(Ataluren; positive contr l) and compounds 1–5 respectively. Cystic fibrosis transmembrane regulator
(CFTR) protein was revealed by a specific antibody targeting its first external loop (secondary antibody
in green, Alexa-488). Nuclei (blue) were DAPI (40,6-diamidino-2-phenylindole) stained.
To this aim, a reporter plasmid (H2B-GFP-opal), in which the cDNA of the H2B gene is fused to
the cDNA of the green fluorescent protein (GFP) harboring a PTC at Trp58 [72], has been generated.
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Hela cells were then transfected with the normal (H2B-GFP) and the mutated (H2B-GFP-opal)
plasmids and treated with selected compounds. The detection of H2BGFP by immunofluorescence
demonstrated the synthesis of a full-length H2BGFP protein and hence the occurrence of readthrough.
These results were confirmed also by western blotting, indicating the achievement of a full-length
protein [29,34,35]. The most active compounds were also tested for nonsense suppression in the cystic
fibrosis bronchial epithelial cell line IB3.1 derived from a CF patient. Also in this case, fluorescence
microscopy demonstrated the readthrough capacity of these compounds with the consequent restoring
of full-length CFTR and its correct localization on the cell membrane (Figure 7B). Moreover, western
blotting was used to quantify the CFTR level, and it confirmed the significant increase in protein level
in cells treated with Ataluren analogues compared to untreated cells [29,34,35].
Once the readthrough activity of Ataluren-like compounds was also confirmed on the CF model,
leading to a significant increase of CFTR expression (compared to untreated cells) and to its correct
location on the cell membrane, the physiological functionality of the recovered protein needed to be
assessed. For this purpose, Fisher rat thyroid (FRT) cells transfected with a plasmid vector harboring
the mutated (G542X) CFTR were used to evaluate expression and activity of the CFTR channel.
Fluorescence microscopy images indicated the readthrough of the PTC and the correct position of
CFTR at the cell membrane; western blotting allowed to quantify the level of CFTR protein. The
functionality of the CFTR channel can be evaluated by two approaches: on one hand, FRT cells capable
of di↵erentiating in an epithelium can be used to measure the ion current of chloride ions crossing the
epithelium in an Ussing flux chamber, thus giving a functionality response [73]. On the other hand,
FRT cells expressing EYFP protein (an ectopically expressed mutant form of the yellow fluorescent
protein) can be used for a quench-EYFP assay based on iodide-mediated fluorescence quenching to
evaluate the halide ion flow across the cell membrane [74]. With both approaches an increase in the
functionality of the chloride channel was observed when nonsense CFTR(G542X-opal) FRT cells were
treated with compound one, demonstrating its activity as a TRID [35].
3.3. Miscellanea
Besides oxadiazoles and aminoglycosides, other small molecules have recently been tested as
TRIDs to treat genetic disorders caused by nonsense mutations, and results concerning their activity
are summarized below. Amlexanox (Figure 8), an antiallergic and anti-inflammatory agent that is
administered orally or topically to treat asthma and aphthous ulcers [75–77], was discovered to inhibit
NMD and induce PTC readthrough. Although this double action has been previously described for
geneticin as well as for other TRIDs, Amlexanox is less toxic and active at lower concentrations than
those required for geneticin. Additionally, apparently Amlexanox is somehow specific and does not
interfere with naturally occurring NMD processes. In this way, the increased number of mRNAs
surviving the NMD results in some recovery of a full-length protein [75].
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ece tly, the nucleoside analogue Clitocine (Figure 9) was discovered to induce readthroug with a
TRID activity two to three orders of magnitude higher than gentamici and geneticin [78]. Furthermore,
Clitocine has a greater selectivity towards PTCs than towards normal stop codons. Interestingly,
to exert its readthrough activity, it is necessary that Clitocine is incorporated into mRNA after its
conversion into Clitocine-50-triphosphate. Friesen et al. [78] claim that, surprisingly, the incorporation
of Clitocine in the mRNA seque ce increased the readthrough of PTCs, and that readthrough activity
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was dose-dependent. Moreover, this nucleoside analogue is able to induce the readthrough in tumors
harboring a nonsense mutation onto the p53 gene, thus inhibiting the growth of tumors.
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Other approaches to suppress the e↵ect of nonsense mutations involve genetic engineering
and include the administration of CRISPR-Cas9 (Crispr-ASsociated), a nuclease that cuts DNA in
a sequence-specific manner guided by a complementary sequence of RNA (gRNA). This strategy,
tested for the correction of the CFTR gene, did not lead to su cient repair and introduced issues
concerning the use of appropriate vectors for the administration of the complex [25]. On the other
hand, a recent study reported the use of anticodon engineered transfer RNAs (ACE-tRNA) as a possible
strategy to suppress PTCs and introduced a near-cognate amino acid in the growing peptide chain.
Since ACE-tRNA showed limited interactions with normal stop codons, the use of these engineered
biomolecules represents a promising approach for selective readthrough [79].
4. TRIDMechanism of Action
Considering the factors participating in the translation of protein synthesis, TRIDs can interact with
various biologic targets, a↵ecting the phase in which they are involved and leading to the readthrough
of a PTC. In principle, these targets could be: (i) release factors (RFs), to hinder their interaction with
the stop codon; (ii) ribosomal RNA, to a↵ect the context where PTC/RF or codon/anticodon recognition
occurs; and (iii) messenger or transfer RNA to a↵ect codon/anticodon recognition, either from the
PTC or the anticodon side, thus inducing PTC/anticodon recognition. In the absence of a translational
readthrough inducer, the readthrough of a premature termination codon can occur in about 1% of
cases (tenfold more frequently than readthroughs of normal stop codons) through normal competition
between tRNA and RF for entering the ribosome A-site [22].
Because of their known antibiotic activity, aminoglycosides have been thoroughly studied for
their interaction with the ribosome. Additionally, crystal structures are available that demonstrate
the specific binding site of representative aminoglycosides such as paromomycin [22,80] or geneticin
(G418) [22,81].
On these bases, consensus has been reached upon the readthrough mechanism of
action of aminoglycosides supported by the comparison of di↵erent crystal structures of
ribosome/aminoglycoside and ribosome/RF complexes. In particular, crystal structures demonstrated
that binding of aminoglycosides produces a conformational change in the ribosomal A-site with
flipping of two adenine residues of the rRNA [22,80,81]. Superimposition of this conformationally
changed structure with the crystal structure of the ribosome/RF complex suggests that, in the presence
of aminoglycosides, the RF/ribosome interaction would be encumbered by steric hindrance [22].
Reasonably, although crystal structures of ribosome/ELX-02 have not been recorded, a similar
mechanism has been reported for the readthrough activity of ELX-02 [37].
On the other hand, the structures of oxadiazoleTRIDs are sodi↵erent from those of aminoglycosides
that analogies in their molecular mechanism of action appear unlikely.
Indeed, the molecular mechanism of action of Ataluren, the benchmark oxadiazole TRID, still
demands unequivocal 3D experimental evidence [66]. In fact, recent discussion proposed that Ataluren
binds to the ribosome A-site on the basis of its decreased activity in the presence of tobramycin [66,70].
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Additionally, observed bias in Ataluren-induced tRNA mispairing leading to readthrough, compared
to endogenous mispairing typical of basal readthrough, demonstrated that Ataluren can be selective
towards the insertion of a near-cognate tRNA [70]. However, while these findings are undoubtedly the
(direct or indirect) e↵ect of some interaction between Ataluren and translational processes occurring
in the ribosome, evidence is still lacking about the actual binding of Ataluren on a well-determined
biomolecular target.
In this context and in the lack of crystal data, computational tools are crucial resources to compare
the a nities between structurally-diverse drug candidates and their potential biomolecular targets.
A previous molecular dynamics study simulated the potential interaction between Ataluren
and di↵erent types of PTCs centered on a 33-nucleotide mRNA fragment of the CFTR gene [72].
This study highlighted a more stable interaction with premature UGA codons with respect to UAG
and UAA, in agreement with the experimentally observed higher suppression of opal versus amber
and ochre nonsense mutations [33,72]. The driving forces that stabilize Ataluren/PTC complexes
involve ⇡–⇡ stacking, H-bonding, and hydrophobic van der Waals interactions [72]. Interestingly, a
readthrough activity comparable with that of Ataluren was also observed in its analogues devoid
of fluorine or carboxylic moieties, suggesting that the oxadiazole core itself plays a crucial role as a
pharmacophore [34].
Therefore, Ataluren’s mechanism of action has been further studied through complementary
computational approaches, such as induced fit docking (IFD), quantum polarized ligand docking
(QPLD), and molecular mechanics combined with the generalized Born and surface area continuum
solvation (MM-GBSA) methods, and results were compared with those obtained for a series of
oxadiazole analogues of Ataluren as well as with a series of aminoglycosides [71]. This study
represented the first computational peer comparison of the strength of potential interactions between
each TRID and di↵erent biomolecular targets involved in protein synthesis: the 16S and 18S subunits
of ribosomal RNA, respectively, for bacteria and eukaryotes, the release factor eRF1, and mRNA [71].
Interestingly, both the positioning and the binding energy values associated with each TRID/target
interaction showed that Ataluren/eRF1 interactions were not stable and could not be claimed as a cause
for Ataluren-induced readthrough. Moreover, Ataluren and its analogues showed a tenfold weaker
interaction with the ribosomal RNA compared to the rRNA/aminoglycoside interaction. On the other
hand, the calculated binding energies for mRNA/Ataluren (or its analogues) interactions showed a
marked preference for the UGA PTC as a target binding site [71,72]. This binding is further stabilized
by ⇡–⇡ interactions between the aromatic portions of Ataluren and guanine, present at position –6 with
respect to the UGA PTC, and by hydrogen bonds with uracil, cytosine, and guanine at positions –4, –3,
and +1, respectively. Among these ancillary interactions, the one involving guanine in the –6 position
is the most important to stabilize the binding to the UGA, as demonstrated by a virtual mutagenesis
study that compared binding energies as a function of the genetic context surrounding the premature
termination codon [71].
5. Increasing TRID E ciency
5.1. Nonsense-Mediated mRNA Decay (NMD) Inhibition
Nonsense suppression drugs, hence, reduce the e ciency of translation termination at in-frame
premature termination codons, thereby allowing ribosomes to resume translation elongation and
generate a full-length protein. However, as already highlighted, the e ciency of readthrough can be
limited by nonsense-mediated mRNA decay (NMD) [82].
Restoring the expression of nonsense-mutated genes by inhibition of the nonsense-mediated
decay of transcribed mRNA, thus relying on basal readthrough for the production of a full-length
functional protein, would be too limited to be e↵ective as a therapeutic strategy.
The use of NMD inhibitors in conjunction with TRIDs would allow to overcome this issue and
to increase the quantity of functional full-length protein [83]. This strategy, which is illustrated in
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Figure 10, has the main drawback of potentially inducing the production of, even toxic, mutated
proteins, whose synthesis would have been blocked by the NMD surveillance mechanism [30].Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 11 of 18 
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Several drugs uch as ca↵ein and SMG1 kinase inhibitors have been fou d to attenu te the NMD
pathway by inhibiting Upf1 and Upf1 protein phosphorylation [84]. Inhibition of NMD may enhance
the e↵e t of nonsense suppr s ion drugs to restore pr tein function by increasi g steady-state mRNA
abundance [84].
Some experiments evidenced that attenuation of the NMD pathway strategy to enhance the
translation of full-length proteins could be a very good appro ch, although it probably requires further
improvement in terms of nonsense mRNA target recov ry [84,85]. This approach was recently tested
by tr ating IB3.1 cells (a cystic fibrosis ell model harb ring the W1282X stop mutation) with ca↵eine to
increase levels of nonsense CFTR-mRNA to restore a functional protein produced by PTC suppression
with Ataluren, thus providing a greater therapeutic benefit [86].
5.2. Correctors and Potentiators
The ideal readthrough process would result in the production of a fully functional protein;
therefore, the continuation of protein synthesis beyond the PTC is only the first (necessary) step for
this achievement. In fact, protein functionality also depends on its correct folding, a process that
occurs after the completion of the polypeptide chain. In this context, drugs could be used to correct the
protein conformation if the readthrough, with the introduction of a near-cognate amino acid, causes an
imperfect folding of the protein.
Examples of this approach presented in this paragraph would focus only on the cystic fibrosis
transmembrane regulator (CFTR) protein. For instance, “CFTR correctors” can actwith twomechanisms:
binding CFTR protein and promoting its correct folding andmaturation, such as Lumacaftor (Figure 11),
or modulating some phases of protein regulation [25].
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details of molecular drug–target interactions would hopefully explain discrepancies in the observed 
activity of drug candidates or even suggest further directions for TRID development. Indeed, efficacy 
of the readthrough process could depend on the identity of the premature stop codon as well as on 
the context surrounding it. For this reason, a careful screening of patients’ gene sequence, together 
with in vitro readthrough activity data collected on patients’ isolated cells, will be relevant to confirm 
such hypotheses. Moreover, the readthrough drug should not interfere with the recognition of 
normally positioned stop codons, thus allowing for the correct termination of protein synthesis. 
Finally, recovered polypeptides should preserve the functionality of the wild-type protein. Several 
solutions have been proposed to tackle this challenge, by means of small molecules (e.g., 
aminoglycosides and oxadiazoles) or genetic engineering (e.g., CRISPR-Cas and ACE-tRNAs) 
approaches. Aminoglycoside antibiotics are able to induce the readthrough of premature stop codons 
by interacting with the small unit of the ribosome. However, their lack of selectivity may cause the 
readthrough of normal stop codons and increase their toxicity, hindering their application for 
prolonged therapies. This issue might have been addressed by the discovery of ELX-02, a glycoside 
that has been reported both as a TRID and inhibitor of NMD, although structural details on its 
supposed interaction with the ribosome need further in-depth studies.  
On the other hand, oxadiazole TRIDs were more selective than aminoglycosides in inducing the 
readthrough of premature but not normal stop codons. Moreover, they did not show the toxicity of 
aminoglycosides and were active at lower dosages. However, no crystal structure is available to 
confirm their binding site on the biomolecular target. Interaction of oxadiazole TRIDs with mRNA 
has been proposed on the basis of computational studies showing differences with the other classes 
of TRIDs and highlighting stabilizing interactions involving the genomic context surrounding the 
PTC.  
As for genetic engineering approaches, the use of ACE-tRNA, based on anticodon recognition, 
could resolve selectivity issues towards the identity of the PTC, and selectivity towards premature 
vs. normal stop codon, but could raise issues of off-target activity. Moreover, at this stage, costs 
associated with this approach appear significantly higher if compared with those involved with the 
development of small TRIDs. 
In summary, TRIDs currently represent the most promising strategy to achieve the synthesis of 
a full-length protein from nonsense-mutated genes. Although it is still possible that the produced 
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Co bined use of both potentiators and correctors has also been proposed, although the costs of
these types of therapies have been esti ated above 300,000 S per year. These functions could be
joined in dual-acting olecules that are cleaved by intestinal hydrolytic enzy es producing both the
CFTR corrector and the CFTR potentiator [25].
6. Conclusions and Perspectives
Nonsense mutations are the cause of numerous genetic diseases for which a definite therapy is
still far from being reached. Synergies between chemists, biologists, and physicians are essential to
approach the problem through a holistic perspective. This approach should apply not only to the
improvement of drugs able to induce the readthrough of premature termination codons but also to the
detailed understanding of their mechanism of action. In fact, in this particular research field, details of
molecular drug–target interactions would hopefully explain discrepancies in the observed activity
of drug candidates or even suggest further directions for TRID development. Indeed, e cacy of the
readthrough process could depend on the identity of the premature stop codon as well as on the
context surrounding it. For this reason, a careful screening of patients’ gene sequence, together with
in vitro readthrough activity data collected on patients’ isolated cells, will be relevant to confirm such
hypotheses. Moreover, the readthrough drug should not interfere with the recognition of normally
positioned stop codons, thus allowing for the correct termination of protein synthesis. Finally, recovered
polypeptides should preserve the functionality of the wild-type protein. Several solutions have been
proposed to tackle this challenge, by means of small molecules (e.g., aminoglycosides and oxadiazoles)
or genetic engineering (e.g., CRISPR-Cas and ACE-tRNAs) approaches. Aminoglycoside antibiotics
are able to induce the readthrough of premature stop codons by interacting with the small unit of
the ribosome. However, their lack of selectivity may cause the readthrough of normal stop codons
and increase their toxicity, hindering their application for prolonged therapies. This issue might have
been addressed by the discovery of ELX-02, a glycoside that has been reported both as a TRID and
inhibitor of NMD, although structural details on its supposed interaction with the ribosome need
further in-depth studies.
On the other hand, oxadiazole TRIDs were more selective than aminoglycosides in inducing the
readthrough of premature but not normal stop codons. Moreover, they did not show the toxicity
of aminoglycosides and were active at lower dosages. However, no crystal structure is available to
confirm their binding site on the biomolecular target. Interaction of oxadiazole TRIDs with mRNA has
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been proposed on the basis of computational studies showing di↵erences with the other classes of
TRIDs and highlighting stabilizing interactions involving the genomic context surrounding the PTC.
As for genetic engineering approaches, the use of ACE-tRNA, based on anticodon recognition,
could resolve selectivity issues towards the identity of the PTC, and selectivity towards premature vs.
normal stop codon, but could raise issues of o↵-target activity. Moreover, at this stage, costs associated
with this approach appear significantly higher if compared with those involved with the development
of small TRIDs.
In summary, TRIDs currently represent the most promising strategy to achieve the synthesis of a
full-length protein from nonsense-mutated genes. Although it is still possible that the produced protein
is less functional with respect to the wild-type one, the use of TRIDs would allow to convert a serious
genetic disorder in a milder genetic defect. In this context, further development could be envisaged by
coupling the use of TRIDs with NMD inhibitors, protein folding correctors, or function enhancers.
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Abbreviations
ACE-tRNAs Anticodon engineered transfer RNAs
AT Ataxia telangiectasia
CF Cystic fibrosis
CFTR Cystic fibrosis transmembrane conductance regulator
DAPI 40,6-diamidino-2-phenylindole
DMD Duchenne muscular dystrophy
FTR cells Fisher rat thyroid cells
GFP Green Fluorescent Protein
HS Hurler’s syndrome
IFD Induced Fit Docking
MD Molecular Dynamics
MM-GBSA molecular mechanics /generalized Born and surface area continuum solvation
NMD Nonsense-mediated mRNA decay
NonSups Nonsense suppressors
pFLuc-wt Plasmid firefly luciferase-wild type
PTC Premature stop codon
PTC124 Ataluren or 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl] benzoic acid
QPLD Quantum Polarized Ligand Docking
RF Release factor
RLuc Renilla reniformis luciferase
TRIDs Translational Readthrough-Inducing Drugs
Upf1 Regulator of nonsense transcripts 1
USH Usher’s syndrome
YFP Yellow fluorescent protein
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